XOMA — Xoma Royalty Share News
0.000.00%
Last trade - 00:00- $792.01m
- $808.75m
- $52.15m
Xoma Royalty Corp Expected To Post A Loss Of 30 Cents A Share: Earnings Preview
Brief: XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Xoma Royalty Corp Reports Results For The Quarter Ended In September 30: Earnings Summary
Xoma Royalty Corp Expected To Post A Loss Of 44 Cents A Share: Earnings Preview
Xoma Royalty Corp Reports Results For The Quarter Ended In June: Earnings Summary
Xoma Royalty Corp Expected To Post A Loss Of 27 Cents A Share: Earnings Preview
Brief: Xoma Corp Filed Amendment To Amended Certificate Of Incorporation To Change Name Of Co From "Xoma Corporation" To "Xoma Royalty Corporation"
Brief: XOMA Receives $8.1 Mln Milestone Related To Day One Biopharmaceuticals' Sale Of Its Priority Review Voucher
Xoma Corp Reports Results For The Quarter Ended In March: Earnings Summary
Xoma Corp Expected To Post A Loss Of 81 Cents A Share: Earnings Preview
Brief: XOMA Adds Economic Interests In 3 First-In-Category Assets To Royalty And Milestone Portfolio
Brief: XOMA Earns $9 Million Milestone As FDA Grants Accelerated Approval To Day One’s OJEMDATM
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Xoma Corp Reports Results For The Quarter Ended In December: Earnings Summary
Kinnate Biopharma rises as co to be acquired by XOMA Corp
Brief: Xoma Enters Into Agreement To Acquire Kinnate Biopharma
Brief: Kinnate Biopharma Inc. Enters Into Agreement To Be Acquired By Xoma Corporation
Brief: XOMA Expands Commercial Royalty And Milestone Portfolio With DSUVIA Acquisition
Brief: XOMA Makes $1 Mln Milestone Payment To Ladrx